

=> d his

(FILE 'HOME' ENTERED AT 15:27:06 ON 03 OCT 2003)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUASCI,
BIOBUSINESS, BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA,
CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB,
DDFU, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, ...' ENTERED AT 15:27:24 ON
03 OCT 2003

SEA DESATURASE

11 FILE ADISCTI
2 FILE ADISINSIGHT
2 FILE ADISNEWS
849 FILE AGRICOLA
13 FILE ANABSTR
110 FILE AQUASCI
92 FILE BIOBUSINESS
27 FILE BIOCOMMERCE
3094 FILE BIOSIS
321 FILE BIOTECHABS
321 FILE BIOTECHDS
912 FILE BIOTECHNO
1286 FILE CABA
314 FILE CANCERLIT
3556 FILE CAPLUS
73 FILE CEABA-VTB
2 FILE CEN
20 FILE CIN
94 FILE CONFSCI
8 FILE CROPB
92 FILE CROPU
14 FILE DDFB
79 FILE DDFU
4033 FILE DGENE
14 FILE DRUGB
110 FILE DRUGU
1 FILE DRUGUPDATES
28 FILE EMBAL
1675 FILE EMBASE
1092 FILE ESBIODASE
107 FILE FEDRIP
240 FILE FROSTI
236 FILE FSTA
4623 FILE GENBANK
1 FILE HEALSAFE
222 FILE IFIPAT
1491 FILE JICST-EPLUS
6 FILE KOSMET
704 FILE LIFESCI
1 FILE MEDICONF
3656 FILE MEDLINE
10 FILE NIOSHTIC
11 FILE NTIS
8 FILE NUTRACEUT
17 FILE OCEAN
1067 FILE PASCAL
2 FILE PHAR
16 FILE PHIN
67 FILE PROMT
1 FILE RDISCLOSURE
2566 FILE SCISEARCH
1007 FILE TOXCENTER

1310 FILE USPATFULL
49 FILE USPAT2
13 FILE VETU
241 FILE WPIDS
241 FILE WPINDEX

L1 QUE DESATURASE

FILE 'DGENE, MEDLINE, CAPLUS, BIOSIS, SCISEARCH, EMBASE, JICST-EPLUS,
USPATFULL' ENTERED AT 15:28:17 ON 03 OCT 2003

L2 1998 S L1 AND STEAROYL-COA
L3 271 S L2 AND PROMOTER
L4 174 DUP REM L3 (97 DUPLICATES REMOVED)

FILE 'MEDLINE, CAPLUS, BIOSIS, SCISEARCH, EMBASE, JICST-EPLUS, USPATFULL'
ENTERED AT 15:29:36 ON 03 OCT 2003

L5 1872 S L1 AND STEAROYL-COA
L6 249 S L5 AND PROMOTER
L7 143 S L6 AND (ISOLAT? OR CHARACTE?)
L8 109 DUP REM L7 (34 DUPLICATES REMOVED)
L9 76 S L8 AND HUMAN

=> d 19 ibib ab 66-76

L9 ANSWER 66 OF 76 USPATFULL on STN

ACCESSION NUMBER: 2000:53893 USPATFULL
TITLE: Compositions for the treatment of body weight disorders including obesity
INVENTOR(S): Tartaglia, Louis Anthony, Watertown, MA, United States
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6057109		20000502
APPLICATION INFO.:	US 1998-210681		19981214 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-946719, filed on 8 Oct 1997 which is a division of Ser. No. US 1997-807861, filed on 26 Feb 1997, now patented, Pat. No. US 5853975 which is a continuation-in-part of Ser. No. US 1995-518878, filed on 23 Aug 1995, now patented, Pat. No. US 5702902 which is a continuation-in-part of Ser. No. US 1995-470868, filed on 6 Jun 1995, now patented, Pat. No. US 5861485 which is a continuation-in-part of Ser. No. US 1994-294522, filed on 23 Aug 1994, now patented, Pat. No. US 5741666		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Yucel, Remy		
LEGAL REPRESENTATIVE:	Pennie & Edmonds LLP		
NUMBER OF CLAIMS:	4		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	30 Drawing Figure(s); 25 Drawing Page(s)		
LINE COUNT:	5331		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

AB The present invention relates to methods and compositions for the treatment of body weight disorders, including, but not limited to, obesity. Specifically, the present invention identifies and describes genes which are differentially expressed in body weight disorder states, relative to their expression in normal, or non-body weight disorder states, and/or in response to manipulations relevant to appetite and/or weight regulation. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in body weight disorders and/or appetite and/or body weight regulation. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of body weight disorders. Additionally, the present invention describes methods for the diagnostic evaluation and prognosis of various body weight disorders, and for the identification of subjects exhibiting a predisposition to such conditions.

L9 ANSWER 67 OF 76 USPATFULL on STN

ACCESSION NUMBER: 2000:1698 USPATFULL
TITLE: **Desaturase** antigen of mycobacterium tuberculosis
INVENTOR(S): Jackson, Mary, Paris, France
Gicquel, Brigitte, Paris, France
PATENT ASSIGNEE(S): Institut Pasteur, Paris, France (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6010855		20000104
APPLICATION INFO.:	US 1997-917299		19970725 (8)

	NUMBER	DATE
--	--------	------

PRIORITY INFORMATION: US 1996-22713P 19960726 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Achutamurthy, Ponnathapura
ASSISTANT EXAMINER: Nashed, Nashaat T.
LEGAL REPRESENTATIVE: Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT: 1192

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the **isolation** of a new gene, **des**, which encodes a M. tuberculosis protein named DES. The **des** gene appears to be conserved among different Mycobacteria species. The amino acid sequence of the DES protein contains two sets of motifs that are **characteristic** of the active sites of enzymes from the class II diiron-oxo protein family. Among this family of proteins, DES shares significant homology with soluble stearoyl-ACP **desaturases**. DES is a highly antigenic protein, which is recognized by **human** sera from patients infected with M. tuberculosis and M. leprae but not by sera from tuberculous cattle. Thus, the DES protein provides a useful tool for the serodiagnostic analysis of tuberculosis.

L9 ANSWER 68 OF 76 USPATFULL on STN

ACCESSION NUMBER: 1999:110533 USPATFULL
TITLE: Fatty acid **desaturase** genes from plants
INVENTOR(S): Browse, John, Palouse, WA, United States
Grau, Luis Perez, Davis, CA, United States
Kinney, Anthony J., Wilmington, DE, United States
Pierce, Jr., John W., Wilmington, DE, United States
Wierzbicki, Anna M., Wilmington, DE, United States
Yadav, Narendra S., Chadds Ford, PA, United States
PATENT ASSIGNEE(S): E. I. du Pont de Nemours and Company, Wilmington, DE,
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5952544		19990914
	WO 9311245		19930610
APPLICATION INFO.:	US 1994-244205		19940826 (8)
	WO 1992-US10284		19921203
			19940826 PCT 371 date
			19940826 PCT 102(e) date
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1991-804259, filed on 4 Dec 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	McElwain, Elizabeth F.		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
LINE COUNT:	4676		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The preparation and use of nucleic acid fragments encoding fatty acid **desaturase** enzymes are described. The invention permits alteration of plant lipid composition. Chimeric genes incorporating such nucleic acid fragments with suitable regulatory sequences may be used to create transgenic plants with altered levels of unsaturated fatty acids.

L9 ANSWER 69 OF 76 USPATFULL on STN

ACCESSION NUMBER: 1999:27456 USPATFULL
TITLE: Pheromone **desaturases**
INVENTOR(S): Knipple, Douglas C., Geneva, NY, United States
Roelofs, Wendell L., Geneva, NY, United States
Miller, Stuart J., Geneva, NY, United States

PATENT ASSIGNEE(S): Cornell Research Foundation, Inc., Ithaca, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5876994		19990302
APPLICATION INFO.:	US 1995-558823		19951116 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Wax, Robert A.		
ASSISTANT EXAMINER:	Nashed, Nashaat T.		
LEGAL REPRESENTATIVE:	Nixon, Hargrave, Devans & Doyle LLP		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	16 Drawing Figure(s); 14 Drawing Page(s)		
LINE COUNT:	1634		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to **isolated** membrane-associated acyl-CoA **desaturases** expressed in the pheromone gland of an insect and, in particular, the **.DELTA.11 desaturase** of *Trichoplusia ni*. The present invention further relates to an **isolated** DNA molecule encoding the T. ni **.DELTA.11 desaturase**, expression vectors comprising the DNA molecule, and host cells comprising the expression vectors. Methods for **isolating** DNA sequences of homologous acyl-CoA **desaturases** expressed in the pheromone glands of insects are provided. The use of these acyl-CoA **desaturases**, DNA molecules, expression vectors, and host cells to produce an unsaturated fatty acyl-CoA product from a saturated or unsaturated fatty acyl-CoA reactant is also disclosed. The unsaturated fatty acyl-CoA products are useful as pheromones or as pheromone precursors as well as in the preparation of organic molecules, such as drugs.

L9 ANSWER 70 OF 76 USPATFULL on STN

ACCESSION NUMBER: 1999:7472 USPATFULL
TITLE: Polypeptides involved in body weight disorders, including obesity
INVENTOR(S): Tartaglia, Louis Anthony, Waterstown, MA, United States
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5861485		19990119
APPLICATION INFO.:	US 1995-470868		19950606 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-294522, filed on 23 Aug 1994		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Draper, Garnette D.		
LEGAL REPRESENTATIVE:	Pennie & Edmonds		
NUMBER OF CLAIMS:	10		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	25 Drawing Figure(s); 21 Drawing Page(s)		
LINE COUNT:	4106		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods and compositions for the treatment of body weight disorders, including, but not limited to, obesity. Specifically, the present invention identifies and describes genes which are differentially expressed in body weight disorder states, relative to their expression in normal, or non-body weight disorder states, and/or in response to manipulations relevant to appetite and/or weight regulation. Further, the present invention identifies and describes genes via the ability of their gene products to interact with

gene products involved in body weight disorders and/or appetite and/or body weight regulation. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of body weight disorders. Additionally, the present invention describes methods for the diagnostic evaluation and prognosis of various body weight disorders, and for the identification of subjects exhibiting a predisposition to such conditions.

L9 ANSWER 71 OF 76 USPATFULL on STN

ACCESSION NUMBER: 1998:162248 USPATFULL
 TITLE: Methods for identifying compositions for the treatment of body weight disorders, including obesity
 INVENTOR(S): Tartaglia, Louis Anthony, Watertown, MA, United States
 PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5853975		19981229
APPLICATION INFO.:	US 1997-807861		19970226 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-518878, filed on 23 Aug 1995, now patented, Pat. No. US 5702902, issued on 30 Dec 1997 which is a continuation-in-part of Ser. No. US 1995-470868, filed on 6 Jun 1995 which is a continuation-in-part of Ser. No. US 1994-294522, filed on 23 Aug 1994, now patented, Pat. No. US 5741666, issued on 21 Apr 1998		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Railey, II, Johnny F.		
LEGAL REPRESENTATIVE:	Pennie & Edmonds LLP		
NUMBER OF CLAIMS:	7		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	38 Drawing Figure(s); 25 Drawing Page(s)		
LINE COUNT:	5111		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods and compositions for the treatment of body weight disorders, including, but not limited to, obesity. Specifically, the present invention identifies and describes genes which are differentially expressed in body weight disorder states, relative to their expression in normal, or non-body weight disorder states, and/or in response to manipulations relevant to appetite and/or weight regulation. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in body weight disorders and/or appetite and/or body weight regulation. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of body weight disorders. Additionally, the present invention describes methods for the diagnostic evaluation and prognosis of various body weight disorders, and for the identification of subjects exhibiting a predisposition to such conditions.

L9 ANSWER 72 OF 76 USPATFULL on STN

ACCESSION NUMBER: 1998:131612 USPATFULL
 TITLE: Adipogenic differentiation of human mesenchymal stem cells
 INVENTOR(S): Pittenger, Mark F., Severna Park, MD, United States
 PATENT ASSIGNEE(S): Osiris Therapeutics, Inc., Baltimore, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5827740		19981027
APPLICATION INFO.:	US 1996-700753		19960730 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Saunders, David
ASSISTANT EXAMINER: VanderVegt, F. Pierre
LEGAL REPRESENTATIVE: Herron, Charles J., Olstein, Elliot M.
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT: 763

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A composition which comprises **human** mesenchymal stem cells which have the potential to differentiate into cells of more than one connective tissue type and a composition which induces cells from the mesenchymal stem cell population to differentiate into the adipogenic lineage, and a process for inducing such differentiation. The composition for inducing such differentiation comprises a glucocorticoid and a compound which stimulates cAMP production or inhibits cAMP degradation (such as a phosphodiesterase inhibitor). The process can further include **isolating** the adipocytes from remaining hMSCs.

L9 ANSWER 73 OF 76 USPATFULL on STN

ACCESSION NUMBER: 1998:61819 USPATFULL
TITLE: Nucleotide sequence of soybean stearoyl-ACP
desaturase gene

INVENTOR(S): Hitz, William D., Wilmington, DE, United States
Yadav, Narendra S., Wilmington, DE, United States
Perez-Grau, Luis, Wilmington, DE, United States

PATENT ASSIGNEE(S): E. I. du Pont de Nemours and Company, Wilmington, DE,
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5760206		19980602
APPLICATION INFO.:	US 1995-474587		19950607 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1992-995657, filed on 11 Dec 1992, now patented, Pat. No. US 5443974		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Benzion, Gary
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
LINE COUNT: 2242

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The preparation and use of nucleic acid fragments encoding soybean seed stearoyl-ACP **desaturase** enzyme or its precursor to modify plant oil composition are described. Chimeric genes incorporating such nucleic acid fragments and suitable regulatory sequences may be utilized to transform plants to control the levels of saturated and unsaturated fatty acids.

L9 ANSWER 74 OF 76 USPATFULL on STN

ACCESSION NUMBER: 1998:42238 USPATFULL
TITLE: Compositions and methods, for the treatment of body weight disorders, including obesity

INVENTOR(S): Tartaglia, Louis Anthony, Waterstown, MA, United States
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5741666		19980421
APPLICATION INFO.:	US 1994-294522		19940823 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		

PRIMARY EXAMINER: Elliott, George G.
ASSISTANT EXAMINER: Railey, II, Johnny F.
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1,7,8
NUMBER OF DRAWINGS: 22 Drawing Figure(s); 18 Drawing Page(s)
LINE COUNT: 3814

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods and compositions for the treatment of body weight disorders, including, but not limited to, obesity. Specifically, the present invention identifies and describes genes which are differentially expressed in body weight disorder states, relative to their expression in normal, or non-body weight disorder states, and/or in response to manipulations relevant to appetite and/or weight regulation. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in body weight disorders and/or appetite and/or body weight regulation. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of body weight disorders. Additionally, the present invention describes methods for the diagnostic evaluation and prognosis of various body weight disorders, and for the identification of subjects exhibiting a predisposition to such conditions.

L9 ANSWER 75 OF 76 USPATFULL on STN

ACCESSION NUMBER: 97:123044 USPATFULL
TITLE: Methods for the diagnosis of body weight disorders including obesity
INVENTOR(S): Tartaglia, Louis Anthony, Watertown, MA, United States
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5702902		19971230
APPLICATION INFO.:	US 1995-518878		19950823 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-470868, filed on 6 Jun 1995 which is a continuation-in-part of Ser. No. US 1994-294522, filed on 23 Aug 1994		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Fleisher, Mindy		
ASSISTANT EXAMINER:	Railey, II, Johnny F.		
LEGAL REPRESENTATIVE:	Pennie & Edmonds LLP		
NUMBER OF CLAIMS:	11		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	26 Drawing Figure(s); 22 Drawing Page(s)		
LINE COUNT:	4032		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods and compositions for the treatment of body weight disorders, including, but not limited to, obesity. Specifically, the present invention identifies and describes genes which are differentially expressed in body weight disorder states, relative to their expression in normal, or non-body weight disorder states, and/or in response to manipulations relevant to appetite and/or weight regulation. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in body weight disorders and/or appetite and/or body weight regulation. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of body weight disorders. Additionally, the present invention describes methods for the diagnostic evaluation and prognosis of various body weight disorders, and for the identification of subjects exhibiting a predisposition to such conditions.

L9 ANSWER 76 OF 76 USPATFULL on STN

ACCESSION NUMBER: 95:75885 USPATFULL

TITLE: Nucleotide sequence of soybean stearyl-ACP
desaturase gene

INVENTOR(S): Hitz, William D., Wilmington, DE, United States
Yadav, Narendra S., Wilmington, DE, United States
Perez-Grau, Luis, Wilmington, DE, United States

PATENT ASSIGNEE(S): E. I. Du Pont de Nemours and Company, Wilmington, DE,
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5443974		19950822
APPLICATION INFO.:	US 1992-995657		19921211 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1990-529049, filed on 25 May 1990, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Benzion, Gary		
NUMBER OF CLAIMS:	13		
EXEMPLARY CLAIM:	1		
LINE COUNT:	2172		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The preparation and use of nucleic acid fragments encoding soybean seed
stearyl-ACP **desaturase** enzyme or its precursor to modify
plant oil composition are described. Chimeric genes incorporating such
nucleic acid fragments and suitable regulatory sequences may be utilized
to transform plants to control the levels of saturated and unsaturated
fatty acids.